Monthly Darbepoetin Alfa: A Preferred Choice Among CKD Patients

Assessing the safety and efficacy of darbepoetin alfa over a three-year period in CKD

Monthly Darbepoetin Alfa: A Preferred Choice Among CKD Patients

A post-marketing surveillance study evaluated the safety and effectiveness of long-term darbepoetin alfa for the treatment of renal anemia *

Ensuring Safety Across Time: Long-Term Viability of Darbepoetin Alfa

Low AEs with High Hemoglobin

Darbepoetin Alfa Biosimilar, offers improved, convenient, and affordable treatment for renal anemia

Abbreviations: ▼

AE: Adverse event; CKD: Chronic kidney disease; CV: Cardiovascular; DCGI: Drug Controller General of India; eGFR: Estimated glomerular filtration rate; GMP: Good manufacturing practice; Hb: Hemoglobin; ISO: International Organization for Standardization; PD: Pharmacodynamics; PK: Pharmacokinetics; WHO: World Health Organization.

References:▼

1. Hoggard J, Crouch T, McMurray S, et al. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin. 2006;22(10):2023–2030. 2. Tanaka T, Nangaku M, Imai E, et al. Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: A post-marketing surveillance study in Japan. Clin Exp Nephrol. 2019;23(2):231–243. 3. Cresp. Available at: https://www.cresp.in/development.html. Accessed on: 22 January 2024.

LMRC Code: GGI-CO-A1-AQS-DCVN-BANNERS-A24-0530

Cresp

Cresp®(Biosimilar of darbepoetin alpha), a product by Dr. Reddy's is an erythropoiesis-stimulating agent which helps in treatment of renal anemia in pre-dialysis patients

Monthly Darbepoetin Alfa: A Preferred Choice Among CKD Patients

Monthly Darbepoetin Alfa: A Preferred Choice Among CKD Patients, Nephrology, Nephrologist, Cresp, Darbepoetin Alfa, CKD, Hematology, Hematologist, Dialysis

Related Articles

Login to continue